NGC | Jotup

Breathalyzer Innovations Meet Rising Demand as Cannabis Market Booms

Retrieved on:

星期四, 五月 16, 2024

Cream, Partnership, News, THC, Agreement, Chocolate, CGC, OTC, Canopy Growth, Curaleaf, Financial News, Political lists, Omega, Police, Accreditation, NGC, GACP, Caffeine, CBG, USD, TPA, OTCQX, XMG, Research, Laboratory, Drink, Edible, Data management, Certification, Blood alcohol content, Growth, Lord, TLRY, Cannabis, Dietary supplement

The cannabis market intersects with the breathalyzer industry particularly as legalization trends increase across various regions.

Key Points:

The cannabis market intersects with the breathalyzer industry particularly as legalization trends increase across various regions.
With the growing acceptance and legalization of cannabis for both medical and recreational use, there is an emerging demand for devices that can accurately measure impairment levels due to cannabis consumption.
This need mirrors the demand dynamics seen in the alcohol breathalyzer market.
Technological innovations are being directed towards developing breathalyzers that can accurately detect tetrahydrocannabinol (THC) — the psychoactive component in cannabis.

Curaleaf Reports First Quarter 2024 Results

Retrieved on:

星期四, 五月 9, 2024

Pillar, Table, NGC, Net, News, THC, Depreciation, TSX, Public expenditure, Automation, Cannabis, Tax, Senior, Acquisition, MCO, Purchasing, MSO, GAAP, Growth, Earnout, Security (finance)

NEW YORK, May 9, 2024 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2024. All financial information is reported in accordance with U.S. generally accepted accounting principles (GAAP) and is provided in U.S. dollars unless otherwise indicated.

Key Points:

First quarter 2024 revenue of $339 million, representing an increase of 2% year-over-year and adjusted gross margin(1) of 48%
First quarter 2024 adjusted EBITDA(1) of $77 million, representing 23% of revenue, a 40 basis point improvement year-over-year
NEW YORK, May 9, 2024 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2024.
Boris Jordan, Executive Chairman of Curaleaf, stated, "Consistent with our expectations, first quarter revenue grew 2% to $339 million, and we achieved a 48% adjusted gross margin.
Curaleaf International rebranded Sapphire Clinics to Curaleaf Clinics in the U.K.
Acquired Can4Med, an experienced pharmaceutical wholesaler in Poland to enhance our market presence.
Curaleaf reports its financial results in accordance with GAAP and uses a number of financial measures and ratios when assessing its results and measuring overall performance.

Nilesh Undavia Calls Out GrafTech Board for Continuing to Distort the Record and Mislead Shareholders

Retrieved on:

星期一, 五月 6, 2024

Ambiguity, NGC, Interview, Capital, Annual general meeting, Disclosure, Exercise, BLUE, CARD, GrafTech, Wellington Management Company, AUM, BOCA, UNIVERSAL, Iron, ALL, LNW, EAF, Security (finance)

BOCA RATON, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- Nilesh Undavia, one of the largest shareholders of GrafTech International Ltd. (NYSE: EAF) (“GrafTech” or the “Company”), today issued the following open letter to shareholders of the Company in connection with the election of directors for the Company’s board of directors (the “Board”) at the Company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) to be held on May 9, 2024:

Key Points:

Instead, the Company has tried to distract shareholders by engaging in personal attacks and misrepresenting the truth.
No error would have occurred had the Company returned my calls or answered my emails requesting clarification.
For months, the Company has ignored and dismissed my constructive engagement, which included CEO selection criteria and long-term strategy.
I urge you to vote the BLUE universal proxy card TODAY to elect me, Nilesh Undavia, to the Board.

TWO CALLS FOR RESEARCH FELLOWSHIP APPLICATIONS NOW OPEN

Retrieved on:

星期三, 五月 8, 2024

NGC, Sculpture, Woman, Disability, Exhibition, Research, Library and Archives Canada, Library, Humanities, Publishing, Social, Gender identity, Archive, National Gallery, Indigenous peoples in Canada, Drawing, Indigenous peoples, Rodger

Submit your application by June 9, 2024

Key Points:

Submit your application by June 9, 2024
OTTAWA, ON , May 8, 2024 /CNW/ - Calls for applications for the National Gallery of Canada's (NGC) Rodger and Joann McLennan Canadian War Art Research Fellowship and for the Research Fellowship in Photography are now open.
The NGC's Rodger and Joann McLennan Canadian War Art Research Fellowship supports advanced research in Canadian and Indigenous Canadian war and military art by scholars undertaking publishing, exhibition, and thesis and dissertation work or their equivalent.
Amounting to $CAD 10,000—expenses and/or allowances included—it is valid for one year from September 1, 2024.
The Research Fellowship in Photography supports an interdisciplinary approach to photography and lens-based culture in general.

2024 Sobey Art Award Longlist Announced

Retrieved on:

星期二, 四月 30, 2024

Exhibition, Gallery, NGC, Name, Sobey Art Award, National Gallery, Film industry

"Congratulations to all 30 artists longlisted for the 2024 Sobey Art Award.

Key Points:

"Congratulations to all 30 artists longlisted for the 2024 Sobey Art Award.
"On behalf of the Sobey Art Award Foundation, our warmest congratulations to each of the deserving artists selected for the 2024 longlist," said Bernard Doucet, Executive Director of the Sobey Art Foundation.
"Each year, we look forward to the Sobey Art Award longlist as an incredible way to gain insight into Canada's contemporary cultural makeup.
The 2024 Sobey Art Award shortlist and the names of the jury members will be announced on June 11, 2024.

Methanex Reports Higher First Quarter 2024 Earnings as Methanol Prices Increase

Retrieved on:

星期三, 四月 24, 2024

NGC, Investment, Medicine Hat, Natural gas, Plant, G3, ID, Methanex, Rare-earth element

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- For the first quarter of 2024, Methanex (TSX:MX) (NASDAQ:MEOH) reported net income attributable to Methanex shareholders of $53 million ($0.77 net income per common share on a diluted basis) compared to net income of $33 million ($0.50 net income per common share on a diluted basis) in the fourth quarter of 2023. Net income in the first quarter of 2024 was higher compared to the prior quarter primarily due to a higher average realized price and the positive impact of the mark-to-market portion of share-based compensation due to changes in Methanex's share price. Adjusted EBITDA for the first quarter of 2024 was $160 million and Adjusted net income was $44 million ($0.65 Adjusted net income per common share). This compares with Adjusted EBITDA of $148 million and Adjusted net income of $35 million ($0.52 Adjusted net income per common share) for the fourth quarter of 2023.

Key Points:

Key production and operational highlights during the first quarter include:
Geismar produced 571,000 tonnes in the first quarter of 2024 compared to 587,000 tonnes in the fourth quarter of 2023.
New Zealand produced 277,000 tonnes in the first quarter of 2024 compared to 344,000 tonnes in the fourth quarter of 2023.
Atlas produced 258,000 tonnes (Methanex interest) in the first quarter of 2024 compared to 283,000 tonnes in the fourth quarter of 2023.
Egypt produced 166,000 tonnes (Methanex interest - 83,000 tonnes) in the first quarter of 2024 compared to 40,000 tonnes (Methanex interest - 20,000 tonnes) in the fourth quarter of 2023.

Cannabis Market Flourishes Amid Global Legalization, Driving Concerns About Road Safety

Retrieved on:

星期一, 四月 22, 2024

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Over the past decade, the cannabis market has undergone significant expansion, driven largely by a wave of legalization efforts across the United States and other parts of the world. As state and national governments reassess their legal stance on cannabis, both for medical and recreational use, the industry has seen a surge in legitimacy and economic interest. In the United States, a majority of states have legalized cannabis in some form, reflecting a shift in public opinion and an acknowledgement of the potential medical benefits and revenue generation opportunities. Globally, countries like Canada, Uruguay, and several European nations have moved towards more liberal cannabis policies, further propelling the market's growth. The financial implications of these legalization efforts are substantial and continue to evolve. According to a report by Grand View Research, the global legal cannabis market size was valued at USD 13.2 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 25.5% from 2022 to 2030. Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO), Cronos Group Inc. (NASDAQ: CRON), Canopy Growth Corporation (NASDAQ: CGC), Aurora Cannabis Inc. (NASDAQ: ACB), Curaleaf Holdings, Inc. (OTC: CURLF)

Key Points:

Globally, countries like Canada, Uruguay, and several European nations have moved towards more liberal cannabis policies, further propelling the market's growth.
One of the primary concerns is the correlation between cannabis use and impaired driving.
Studies have shown that cannabis can significantly impair motor coordination, reaction times, and decision making, which are critical skills for safe driving.
NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets.

Quantum Announces Expanded Global Partnership Model to Grow Presence in Asia-Pacific Markets

Retrieved on:

星期二, 四月 30, 2024

Quantum® Corporation (NASDAQ: QMCO), the pioneer in end-to-end data management solutions designed for the AI era, today announced the expansion of its global partnership model across the key markets of South Korea, Japan, Australia and New Zealand.

Key Points:

Quantum® Corporation (NASDAQ: QMCO), the pioneer in end-to-end data management solutions designed for the AI era, today announced the expansion of its global partnership model across the key markets of South Korea, Japan, Australia and New Zealand.
Each of these partners already has a strong foundation with Quantum and deep knowledge of its solutions, with existing joint customers today.
Additionally, Quantum and these partners will continue to offer customers in the region support and services jointly.
This expanded model is to be deployed within the second quarter of calendar year 2024.

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

Retrieved on:

星期四, 四月 11, 2024

FDA, Project, NGC, Safety, Food, Abstract, PCSA, Plasma, Publication, Incidence, Patient, Doctor of Pharmacy, Database, Capecitabine, AACR, AUC, ODR, Breast cancer, Pharmaceutical industry

HANOVER, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, presented two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2024, including new Phase 1b data on its Next Generation Capecitabine (NGC-Cap) product. These abstracts are available in the Publications section of Processa’s website.

Key Points:

The NGC-Cap Phase 1b trial evaluated ascending doses of capecitabine when combined with a fixed dose of PCS6422 in patients with advanced, relapsed, or refractory progressive gastrointestinal cancer.
NGC-Cap demonstrated greater 5-FU (5-fluorouracil) exposure and lower fluoro-beta-alanine (FBAL) exposure with a better or similar side effect profile compared with monotherapy capecitabine.
“The most recent data for the Phase 1b NGC-Cap study presented at AACR highlight NGC-Cap’s ability to distribute more 5-FU to cancer cells with 5-10 times greater systemic exposure than when capecitabine is administered alone.
“This Phase 1b study is ongoing due to continued patient response and we plan to release final trial data once the database is locked.

Curaleaf Completes Acquisition of Northern Green Canada

Retrieved on:

星期一, 四月 22, 2024

NGC, Certification, Hierarchy, TSX, Toronto Stock Exchange, Acquisition, Projection

NEW YORK, April 22, 2024 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada ("NGC"), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company's strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.

Key Points:

The accretive acquisition amplifies the Company's strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.
Integrating NGC's international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.
"We are thrilled to welcome NGC formally to the Curaleaf family of global brands," said Boris Jordan, Founder and Executive Chairman of Curaleaf.
Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.